A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group Multiple-center Study With Additional Open-label Single-blind and Placebo-controlled 24-Week Histology Cohorts to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for Up to 24 Weeks in Patients With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)

Trial Profile

A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group Multiple-center Study With Additional Open-label Single-blind and Placebo-controlled 24-Week Histology Cohorts to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for Up to 24 Weeks in Patients With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2018

At a glance

  • Drugs NGM 282 (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Therapeutic Use
  • Sponsors NGM Biopharmaceuticals
  • Most Recent Events

    • 01 Jun 2018 Number of treatment arms has been changed from 5 to 6 and planned patient number has also increased.
    • 01 Jun 2018 Planned number of patients changed from 140 to 250.
    • 01 Jun 2018 Planned End Date changed from 1 Apr 2018 to 1 Sep 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top